NeuroScopic

22/10/2026

Orgullosos de ser parte. No se pierdan el nuevo formato y precios más económicos.

12/10/2026

En Neuroscopic llevamos casi 20 años previniendo trastornos demenciales (como el Alzheimer), así como casi una década recomendado el uso de dosis bajas de litio para prevención y tratamiento de procesos neurodegenerativos/demencias.

The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia. A Narrative Review
Gregory J. Moore, MD, PhD; Niranjan Bose, PhD; Ioline D. Henter, MA; Husseini K. Manji, M.

IMPORTANCE Lithium, a long-established cornerstone therapy for bipolar disorder, is a biologically plausible disease-modifying agent for neurodegenerative disorders, including mild cognitive impairment (MCI) and Alzheimer disease (AD).
OBSERVATIONS Rather than targeting a single pathology like amyloid or tau, lithium acts across multiple cellular resilience pathways. Chronic lithium exposure induces the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), enhances brain-derived neurotrophic factor (BDNF) signaling, inhibits glycogen synthase kinase-3β (GSK-3β), stabilizes mitochondrial function, and reduces oxidative stress. These convergent mechanisms promote neuronal survival and synaptic integrity. In humans, proton magnetic resonance spectroscopy studies found that lithium increased N-acetylaspartate levels, consistent with improved neuronal viability, and structural magnetic resonance imaging (MRI) studies found that lithium preserved gray matter and/or reversed illness-related atrophy in hippocampal and corticolimbic regions. In addition, extensive evidence demonstrates that low-dose lithium (approximately 0.3mM)—significantly lower than traditional psychiatric doses (0.6-1.0mM)—exerts robust neurotrophic and neuroprotective effects. Preclinical models have found that these concentrations stimulate hippocampal neurogenesis, promote structural plasticity, and protect against proteotoxic injury. Furthermore, epidemiological studies have associated cumulative lithium exposure with reduced dementia risk, and early randomized clinical trials in MCI suggest cognitive stabilization and favorable tau biomarker changes at low, well-tolerated doses. The recent repletion hypothesis suggests that lithium may also function as a physiological trace element, but these findings await independent replication.
CONCLUSIONS AND RELEVANCE These convergent data support a prospective clinical trial of low-dose lithium orotate to slow disease progression in MCI. Such an approach would prioritize established neuroprotective mechanisms while potentially mitigating the kidney
and thyroid risks associated with higher-dose carbonate formulations. If low-dose lithium can indeed meaningfully alter disease trajectory, it would represent a much-needed, accessible, and inexpensive treatment that may be especially relevant in low- and middle-income countries.

https://www.researchgate.net/publication/406894804_The_25-Year_Evolution_of_Lithium_as_a_Disease-Modifying_Agent_in_Dementia_A_Narrative_Review

11/10/2026

👌🏼

Psychiatry remains unusual among medical specialties because its diagnostic categories are defined exclusively by reported symptoms, observed behavior, and functional impairment rather than by validated physiological or pathological markers. Although these classifications may support communication and guide treatment, they only function as descriptive syndromes rather than confirmed disease entities (not what modern medicine is about). Their uncertain biological boundaries, substantial diagnostic overlap, heterogeneity, and limited predictive validity raise serious concerns regarding diagnostic precision and scientific validity. Moreover, the empirical efficacy of many psychiatric treatments is often low, variable, and difficult to predict, while their potential adverse effects can be substantial, sometimes limiting long-term use. Treatment response therefore cannot compensate for inadequate understanding of underlying mechanisms or establish the validity of the diagnostic categories themselves. This epistemic gap may limit prognosis, individualized treatment selection, and causal understanding, while encouraging reliance on trial-and-error intervention. Psychiatry requires substantial reform through more valid diagnostic constructs, improved biological and psychological models, clinically meaningful biomarkers, stronger treatment-prediction methods, systematic evaluation of harms, and greater transparency regarding uncertainty. Its development should prioritize explanatory validity, treatment safety, and patient-centered outcomes rather than merely refining symptom-based classification systems.
NeurocienciaNews

30/09/2026

El campo de la psiquiatría es el único campo médico que no se enfoca en enfermedades (no existen enfermedades psiquiátricas), por lo cual necesitamos ser muy cautelosos sobre todo lo que tiene que ver con este campo cuasi-científico.

Sobre la psiquiatría: Diagnóstico, tratamiento y otros temas. Una breve conversación con Gemini. Esperamos que sea de utilidad.
https://share.google/aimode/WsiFj5owf87H4aDDF

Centro de Neurodiagnóstico Integral.
Tel: (81)8143-0754. WhatsApp: 81 3621 7142
Dr. Sepulveda 140. Int 2

13/09/2026

Recerebrando y honrando a uno de los grandes

Hoy nace el gran Adolf Meyer, primer director del departamento de psiquiatría del Hospital John Hopkins. Alumno de Forel, Hughlings-Jackson y Charcot: "Those who imagine that all psychiatry and psychopathology and therapy have to resolve themselves into a smattering of claims and hypotheses of psychoanalysis and that they stand or fall with one's feelings about psychoanalysis, are equally misguided". 1928. Desde el inicio hubo muchos que despreciaron al psicoanálisis por ser más un culto y psuedociencia que un campo médico.

09/09/2026

Nos vemos mañana

07/09/2026

Muy recomendado

✨ ¡El momento es ahora!

Las inscripciones están abiertas y tú puedes ser parte del Diplomado Internacional en Neurodesarrollo.

Convocatoria:https://premics.com/wp-content/uploads/2026/08/CONVOCATORIA-DIN-F1.pdf

14/08/2026

Hoy nace uno de los mentores más apreciados del Dr. Carlos Novo, ER John, un matemático muy neuro. Este es el resumen de una platica sobre las bases neurofisiológicas del estado de conciencia en pacientes anestesiados, que dió hace más de 17 años en Monterrey. Fue su último evento internacional antes de morir 10 meses después; por lo que realizamos un evento en octubre del 2009 (año en que murió el 28 de febrero) para honrarlo; la imagen es de dicho evento.

Abstract:
A physiological theory of consciousness has been proposed which is derived from data collected during development of a QEEG instrument for the quantification of the level of conscious awareness during induction, maintenance and emergence from surgical anesthesia with a wide variety of agents. Such studies revealed invariant reversible QEEG changes during the loss and return of consciousness which contributed to better understanding of the neurophysiology of anesthetic action. These changes constituted quantifiable departure from and return to the established normative data of the eyes closed EEG, for the chronological age corresponding to that of the patient. In conjunction with existing knowledge of the neurophysiological generation of the EEG and current neurobiological research findings, this enabled development of a model of the neuroanatomical and neurochemical structure of the homeostatic system regulating the frequency composition and other features known to be descriptive of the resting EEG of healthy normally functioning persons independent of their ethnic or cultural background.
It was then postulated that this system not only dynamically stabilizes the steady state of the brain electrical activity, but that consciousness is somehow produced by and depends upon this electrical brain state. The normative QEEG descriptors were considered to define the Ground State of the healthy resting human brain.
Initially, this postulate was supported only by the essentially experimental observations during anesthesia and the observations by others as well as ourselves of QEEG abnormalities relative to normative data consistently found in patients with a wide diversity of altered mental states and their responses to treatment. Successful return of the QEEG to the Ground State has achieved by this approach in two patients in coma after prolonged hypoxia, considered clinically to be permanently vegetative. This theory and the supporting evidence will be presented in a companion symposium at this meeting.

10/08/2026

Tener diagnósticos basados en función cerebral es la meta.

On average, it can take seven years for someone with depression to find a treatment that works.

Today's podcast guest, Stanford University Stanford Psychiatry and Behavioral Sciences Leanne Williams, is working to change that. Her research uses brain imaging to identify different forms of depression and explore how those differences could help guide more targeted treatments.

Williams leads the Stanford PMHW and a new international task force working to transform mental health diagnosis and treatment using biological data and brain imaging.

We discuss what it could take to move mental health care beyond trial and error and toward more precise, personalized treatment.

Listen now: https://neuroscience.stanford.edu/news/how-brain-imaging-transforming-mental-health

27/07/2026

Prevención siempre será la mejor medicina

The World Health Organization (WHO) has launched the second edition of its Guidelines for Risk Reduction of Cognitive Decline and Dementia. can access here: https://bit.ly/4vDXOjF

is pleased to share these updated guidelines, to which members of the ADI team contributed during their development. The guidelines were launched during a WHO-hosted webinar highlighting the latest evidence on dementia risk reduction, including newly recognised evidence-based risk factors and a new framework for grouping risk factors into four categories: behaviours, health conditions and biological states, environmental, and multidomain. This new framework reflects a more holistic understanding of dementia risk and opportunities for intervention.

Joining the launch was ADI Acting CEO, Chris Lynch, who discussed the important role of civil society and dementia advocacy organisations in raising awareness of dementia risk reduction. He also highlighted the importance of integrating dementia into broader messaging around noncommunicable disease (NCD) prevention and risk reduction.

During the webinar, Dr Tarun Dua, WHO Unit Head for Neurological, Sensory and Oral Conditions in the Department of Noncommunicable Diseases and Mental Health, emphasised the importance of adapting global guidance to local contexts:

"These guidelines are global, but we must go local."

Following the release of these guidelines, ADI invites our global network to join us for a special webinar, "Advancing Dementia Risk Reduction: Implementing the WHO's Updated Guidelines." This live, expert-led session will provide an in-depth overview of the new recommendations and showcase practical examples from national dementia associations, demonstrating how these global guidelines can be successfully implemented at the local level.

Register for the webinar today:
https://bit.ly/4xNkSic